SRPT241101C97000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Business And Shares Still Trailing The Industry
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Baird Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Optimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative Potential
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
S&P 500 Futures Fall In Premarket Trading; Range Resources, Mueller Industries Lead
Sarepta a New Buy at Jefferies on Muscular Dystrophy Franchise, Pipeline
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Unveiling 15 Analyst Insights On Sarepta Therapeutics
RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $182
RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)
Jefferies Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $165
Sarepta Therapeutics: Strong Buy Recommendation Driven by Expanding Elevidys Sales and Promising Pipeline
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
Needham Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $205
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Buy Rating on Sarepta Therapeutics: Promising Long-Term Data and Market Opportunity Amid Stock Weakness